Recent Nature publications highlight the groundbreaking performance of RareCyte’s Orion Spatial Biology platform RareCyteAvery WilliamsSeptember 26, 20232023
Rarecyte Selected for The Wellcome Leap in Utero Program; Will Utilize its Rare Cell Liquid Biopsy Platform to Perform Breakthrough Research to Decrease Stillbirth Rates Worldwide RareCyteAvery WilliamsNovember 14, 20222022
RareCyte® Secures $24M Financing to Advance the Orion™ Spatial Biology Platform and Expand Global Commercial Channels RareCyteAvery WilliamsSeptember 9, 20212021
RareCyte® announces the Orion™ spatial biology platform with breakthrough technology for same-day highly multiplexed tissue analysis RareCyteAvery WilliamsJuly 17, 20202020
RareCyte Closes $22M Financing for Global Commercialization and Platform Expansion into Tissue Multiplexing RareCyteAvery WilliamsDecember 19, 20192019
